AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01256359
Drug: Docetaxel and placebo
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
Trial: NCT01844401
Drug: Albuterol Spiromax®
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
Trial: NCT00327730
Drug: Eperisone
RxNorm normalized name: Eperisone
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01354743
Drug: Dysport
RxNorm normalized name: Dysport
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits.
Trial: NCT03164564
Drug: Oral CAB
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAB 30 mg tablet
Trial: NCT03164564
Drug: CAB LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
Trial: NCT03557931
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral or depot administration
Trial: NCT03557931
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03557931
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral or depot administration
Trial: NCT03557931
Drug: ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral or depot administration
Trial: NCT03557931
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral or depot administration
Trial: NCT03557931
Drug: brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration
Trial: NCT03557931
Drug: paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral or depot administration
Trial: NCT03557931
Drug: lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration
Trial: NCT01656330
Drug: Rivaroxaban 20 mg twice daily
RxNorm normalized name: rivaroxaban 20 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
Trial: NCT01656330
Drug: Rivaroxaban 20 mg once daily
RxNorm normalized name: lisinopril
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
Trial: NCT04274244
Drug: Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks.
Trial: NCT04274244
Drug: Enamel Matrix Proteins (Active comparator group)
RxNorm normalized name: Matrix
DrugBank: Matrix-M (DB16369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative periodontal therapy + Enamel matrix proteins:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks.
Trial: NCT00532350
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01490502
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
Trial: NCT01519492
Drug: AFN-12520000
RxNorm normalized name: AFN-1252
DrugBank: AFN-1252 (DB12658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
Trial: NCT04393298
Drug: ginisortamab
RxNorm normalized name: Ginisortamab
DrugBank: Ginisortamab (DB18863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.
Trial: NCT04643925
Drug: Ovitrelle
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
Trial: NCT00455585
Drug: nevirapine, stavudine, lamivudine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01293292
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
Trial: NCT01860040
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkylating antineoplastic agent (Chemotherapy)
Trial: NCT01860040
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antimetabolite antineoplastic agent (Chemotherapy)
Trial: NCT01860040
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antimetabolite antineoplastic agent (Chemotherapy)
Trial: NCT02394340
Drug: Omeprazole 40 mg
RxNorm normalized name: omeprazole 40 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule to be taken as per the instructions regarding proper dosing technique.
Trial: NCT02394340
Drug: Luliconazole Cream 1%
DrugBank: Luliconazole (DB08933)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical cream to be applied as per the instructions regarding proper study drug application technique.
Trial: NCT02331602
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
Trial: NCT02331602
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
Trial: NCT00644306
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/day continuously for 18 months
Trial: NCT00644306
Drug: melphalan, prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
Trial: NCT00644306
Drug: melphalan, prednisone, thalidomide
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
Trial: NCT02470065
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once daily afatinib at a dose of 40 mg for 8 weeks
Trial: NCT04558190
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta2-agonist infusion
Trial: NCT02418247
Drug: I131
RxNorm normalized name: I131-KAb201
DrugBank: KAb201 (DB17210)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02418247
Drug: I123
RxNorm normalized name: sodium iodide I123
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00742079
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
Trial: NCT00595504
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
Trial: NCT00863148
Drug: Clofarabine in combination with IV busulfan and ATG
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
Trial: NCT01183208
Drug: Intervention A
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
Trial: NCT00141739
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant.
Trial: NCT03331484
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily
Trial: NCT03331484
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
Trial: NCT01662063
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
Trial: NCT00336141
Drug: Suberoylanilide hydroxamic acid
RxNorm normalized name: Suberoylanilide hydroxamic acid
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg QD (every day) for five days, followed by 9 days of no vorinostat
Trial: NCT01183208
Drug: Intervention D
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 g TOPICAL CREAM [AGE INTERVENTION DUALITY]
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
Trial: NCT01183208
Drug: Intervention E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
Trial: NCT04590508
Drug: Xanthohumol
RxNorm normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The xanthohumol supplement will be administered in a capsule and taken orally.
Trial: NCT01188824
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, bid p.o.
Trial: NCT02897479
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
Trial: NCT04492358
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
Trial: NCT04492358
Drug: Prednisone tablet
RxNorm normalized name: Prednisone Tablets
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 60 mg/day, in a single dose, during 3 days
Trial: NCT01520402
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
Trial: NCT01083706
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC or IV
Trial: NCT02819102
Drug: BCX7353 and probes
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00108238
Drug: Raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01211457
Drug: sapacitabine and decitabine (Part 1 - completed)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: decitabine will be administered in alternating cycles with sapacitabine
Trial: NCT01211457
Drug: sapacitabine and venetoclax (Part 2 - recruiting)
DrugBank: Sapacitabine (DB06365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sapacitabine will be administered concomitantly with venetoclax
Trial: NCT01583686
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Trial: NCT01583686
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Trial: NCT01981525
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
Trial: NCT01538472
Drug: Rituxan
RxNorm normalized name: Rituxan
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8.
Trial: NCT01538472
Drug: BCNU
RxNorm normalized name: BCNU
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m2 by vein on Day -6.
Trial: NCT01538472
Drug: VP -16
RxNorm normalized name: etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
Trial: NCT01538472
Drug: Ara-C
RxNorm normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
Trial: NCT01538472
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg/m2 by vein on Day -1.
Trial: NCT01538472
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
Trial: NCT02923739
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02953743
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Trial: NCT00759460
Drug: Sertindole
RxNorm normalized name: sertindole
DrugBank: Sertindole (DB06144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Trial: NCT00759460
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Trial: NCT00747474
Drug: Lipotecan
RxNorm normalized name: Lipotecan
DrugBank: Lipotecan (DB17385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipotecan IV day 1, 8, 15
Trial: NCT04324346
Drug: FEC75 (or EC90) x 6
RxNorm normalized name: cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type of Chemotherapy
Trial: NCT04324346
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Type of Chemotherapy
Trial: NCT03996057
Drug: Methenamine Hippurate 1000 MG
RxNorm normalized name: methenamine hippurate 1000 MG
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discussed in arm/group description
Trial: NCT03996057
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
Trial: NCT00964990
Drug: JNJ-42160443
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
Trial: NCT02604498
Drug: Nemonoxacin
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 500mg oral
Trial: NCT01925066
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no